Open AccessFalse-Positive Rate in First-Trimester Screening Based on Ultrasound and Cell-Free DNA versus First-Trimester Combined Screening with Additional Ultrasound Markers
Author(s) -
Karl Oliver Kagan,
Vanessa Maier,
Jiri Sonek,
Harald Abele,
Kai Lüthgens,
Maximilian Schmid,
Philipp Wagner,
Markus Hoopmann
Publication year - 2018
Publication title -
fetal diagnosis and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.976
H-Index - 60
eISSN - 1421-9964
pISSN - 1015-3837
DOI - 10.1159/000489121
Subject(s) - ductus venosus , medicine , trisomy , ultrasound , nuchal translucency measurement , obstetrics , cell free fetal dna , gynecology , pregnancy , nasal bone , aneuploidy , gestation , prenatal diagnosis , fetus , radiology , surgery , biology , biochemistry , genetics , gene , chromosome
To determine whether screening for trisomy 21 based on first-trimester combined screening (FTCS) with assessment of nasal bone (NB), tricuspid flow (TCF), and ductus venosus flow (DVF) results in similar false-positive rates compared to ultrasound and cell-free DNA (cfDNA) screening.